Home

témoignage esquisser une tasse de jean pierre issa md calorie cylindre Renforcer

Interview with Dr. Jean-Pierre Issa | CancerQuest
Interview with Dr. Jean-Pierre Issa | CancerQuest

Jean-Pierre Issa, MD, Philadelphia, PA | Oncologist
Jean-Pierre Issa, MD, Philadelphia, PA | Oncologist

Dr. Jean-Pierre Issa, MD | Philadelphia, PA | Internal Medicine | Vitals
Dr. Jean-Pierre Issa, MD | Philadelphia, PA | Internal Medicine | Vitals

Jean-Pierre Issa, MD, Philadelphia, PA | Oncologist
Jean-Pierre Issa, MD, Philadelphia, PA | Oncologist

DNA methylation changes in aging cells and tissues | HSTalks
DNA methylation changes in aging cells and tissues | HSTalks

Dr. Jean-Pierre Issa, MD – Philadelphia, PA | Oncology
Dr. Jean-Pierre Issa, MD – Philadelphia, PA | Oncology

Prof. Jean-Pierre Issa | HSTalks
Prof. Jean-Pierre Issa | HSTalks

Dr. Jean-Pierre Issa, Temple U [IMAGE] | EurekAlert! Science News Releases
Dr. Jean-Pierre Issa, Temple U [IMAGE] | EurekAlert! Science News Releases

The Myelodysplastic Syndrome as an Epigenetic Disease”
The Myelodysplastic Syndrome as an Epigenetic Disease”

Leadership - Epigen Oncology
Leadership - Epigen Oncology

Press Releases
Press Releases

Jean-Pierre J. Issa's research works | Coriell Institute for Medical  Research, Camden and other places
Jean-Pierre J. Issa's research works | Coriell Institute for Medical Research, Camden and other places

Jean-Pierre Issa, MD, Philadelphia, PA | Oncologist
Jean-Pierre Issa, MD, Philadelphia, PA | Oncologist

NOVA | Ghost in Your Genes | Epigenetic Therapy | PBS
NOVA | Ghost in Your Genes | Epigenetic Therapy | PBS

Microbiota Accelerates Age-Related CpG Island Methylation in Colonic Mucosa
Microbiota Accelerates Age-Related CpG Island Methylation in Colonic Mucosa

Jean-pierre Issa, Professor - eMedEvents
Jean-pierre Issa, Professor - eMedEvents

Our Faculty | Jean-Pierre Issa | Coriell Institute
Our Faculty | Jean-Pierre Issa | Coriell Institute

Investigators and Staff
Investigators and Staff

Camden-based Coriell Institute hires Jean-Pierre Issa for CEO post -  Philadelphia Business Journal
Camden-based Coriell Institute hires Jean-Pierre Issa for CEO post - Philadelphia Business Journal

Spotlight On: Jean-Pierre Issa, President and CEO, Coriell Institute for  Medical Research - Capital Analytics
Spotlight On: Jean-Pierre Issa, President and CEO, Coriell Institute for Medical Research - Capital Analytics

Epigenetic Therapies — New Approaches | TRP
Epigenetic Therapies — New Approaches | TRP

Spotlight On: Jean-Pierre Issa, President and CEO, Coriell Institute for  Medical Research - Capital Analytics
Spotlight On: Jean-Pierre Issa, President and CEO, Coriell Institute for Medical Research - Capital Analytics

Coriell CEO Dr. Jean-Pierre Issa outlines his goals for the Camden  Institute - Philadelphia Business Journal
Coriell CEO Dr. Jean-Pierre Issa outlines his goals for the Camden Institute - Philadelphia Business Journal

02 - Research Motivations - Interview with Dr. Jean-Pierre Issa - YouTube
02 - Research Motivations - Interview with Dr. Jean-Pierre Issa - YouTube

Pulling Back the Curtain: Allen Yang, MD, PhD
Pulling Back the Curtain: Allen Yang, MD, PhD

Jean-Pierre J. Issa's research works | Coriell Institute for Medical  Research, Camden and other places
Jean-Pierre J. Issa's research works | Coriell Institute for Medical Research, Camden and other places

TAT 2011 presentation: Discovery and development of next generation  epigenetic DNMT inhibitors: Development of SGI-110, a novel
TAT 2011 presentation: Discovery and development of next generation epigenetic DNMT inhibitors: Development of SGI-110, a novel

Epigenetic Therapy: What Is It, Where Are We, and What Do...
Epigenetic Therapy: What Is It, Where Are We, and What Do...

Dr. Jean-Pierre Issa Details the Positive Impacts of Reducing Caloric  Intake | Temple Health
Dr. Jean-Pierre Issa Details the Positive Impacts of Reducing Caloric Intake | Temple Health

First clinical results of a randomized phase 2 study of SGI-110, a novel  subcutaneous (SQ) hypomethylating agent (HMA), in adult
First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult